The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms

The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms

Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-RE...

Full description

Bibliographic Details
Main Authors: Dilvin Semo, Julius Obergassel, Marc Dorenkamp, Pia Hemling, Jasmin Strutz, Ursula Hiden, Nicolle Müller, Ulrich Alfons Müller, Sajan Ahmad Zulfikar, Rinesh Godfrey, Johannes Waltenberger
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Journal of Clinical Medicine
Subjects:
diabetes mellitus
empagliflozin
SGLT-2
monocytes
endothelial cells
vascular dysfunction
Online Access:https://www.mdpi.com/2077-0383/12/4/1356

Internet

https://www.mdpi.com/2077-0383/12/4/1356

Similar Items